Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Janssen Research & Development, LLC clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
701
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Janssen Research & Development, LLC
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Janssen Research & Development, LLC. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 289–300 of 701 matching trials for sponsor Janssen Research & Development, LLC.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 3 Interventional Results available

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

NCT03517722
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
16 Years to 75 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03227224
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Placebo, JNJ-42847922
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Anaheim, California • Chino, California • Lemon Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04075396
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Duarte, California • Orlando, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

NCT02659098
View directory record Official record
Conditions
Visual Acuity, Geographic Atrophy, Macular Degeneration
Interventions
CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
Drug · Device
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Arcadia, California • Chicago, Illinois • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 2 Interventional Results available

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Ketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 2 Interventional

A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

NCT01823016
View directory record Official record
Conditions
Asthma
Interventions
Placebo, JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

NCT03581916
View directory record Official record
Conditions
Healthy
Interventions
18F-JNJ-64326067
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed Phase 1 Interventional

A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT02968108
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Withdrawn Phase 2 Interventional

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

NCT04655807
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-64304500, Placebo, Adalimumab, Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 2, 2026, 2:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)

NCT03014544
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Computer- administered test battery, Examiner- administered test battery
Device
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 59 Years
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 2, 2026, 2:38 AM EST

About this Janssen Research & Development, LLC sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Janssen Research & Development, LLC is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Janssen Research & Development, LLC trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Janssen Research & Development, LLC.